Business Overview: Profound Medical Corp. (NASDAQ: PROF)

---

Executive Summary

Profound Medical Corp. is a commercial-stage medical device company based in Mississauga, Ontario, Canada, that develops AI-powered, MRI-guided, incision-free thermal ablation systems for treating diseased tissue. Its lead platform, TULSA-PRO, uses transurethral ultrasound to ablate prostate tissue under real-time MRI guidance as a treatment for localized prostate cancer and benign prostatic hyperplasia (BPH); its second platform, Sonalleve, applies MRI-guided focused ultrasound from outside the body, primarily for uterine fibroids.

Although Canadian-headquartered, Profound now files a domestic Form 10-K with the SEC rather than the 40-F typical of a Canadian foreign private issuer, reflecting its deepening U.S. commercial footprint. The company matters less for its current size — full-year 2025 revenue of roughly $16.1 million — and more for the regulatory milestone it reached in 2025: TULSA-PRO became the first MRI-guided therapeutic ultrasound procedure ever to receive Category I CPT codes from the American Medical Association, a reimbursement signal that materially de-risks U.S. hospital adoption.

---

1. Core Business Model & How They Work

Profound sells a capital-equipment-plus-consumable model, similar in structure to a razor-and-blade business but inside a hospital capital-budgeting and reimbursement cycle:

[ Capital Sale of TULSA-PRO / Sonalleve System to Hospital ] ➡️ [ Physician Training & Workflow Integration ] ➡️ [ Recurring Single-Use Device & Service Revenue per Procedure ] ➡️ [ Reimbursement via CPT/HCPCS Codes ] ➡️ [ Clinical Data Generation (e.g., CAPTAIN Trial) ] ➡️ [ Expanded Adoption & Indications ]

Key Operational Drivers

1. Capital Placements Drive the Installed Base: Each TULSA-PRO system sale (management guided to ~120 cumulative installs by the end of 2026, against a stated pipeline of 110 potential new systems) seeds a hospital site for recurring, higher-margin single-use device and service revenue.
2. Distribution Partnerships: Profound sells directly in the U.S. and relies on Philips, GE, and Siemens for lead generation and MRI-suite distribution relationships, since TULSA-PRO and Sonalleve both operate inside an existing MRI scanner rather than as standalone imaging hardware.
3. Reimbursement as a Growth Lever: The 2025 award of three Category I CPT codes (effective January 1, 2025) — one for single-physician TULSA procedures and two for split urologist/radiologist billing — replaced the prior temporary HCPCS code and is the single biggest near-term catalyst for U.S. hospital adoption, since Category I status signals FDA-cleared, clinically proven status to payers.
4. Clinical Evidence Generation: The randomized CAPTAIN trial (TULSA vs. robotic prostatectomy) completed enrollment in 2025 with 211 subjects, building the comparative-effectiveness data needed to expand payer coverage and physician confidence.

---

2. Product Portfolio

---

3. Competitive Landscape

TULSA-PRO competes against a wide range of established and incumbent prostate-disease treatments rather than a narrow set of direct device competitors:

• Surgical options — Open, laparoscopic, and robotic (da Vinci) radical prostatectomy, the long-standing gold-standard whole-gland treatment, carries higher rates of incontinence and erectile dysfunction that TULSA-PRO's incision-free approach is designed to reduce.
• Radiation-based options — External beam radiation, brachytherapy, and high-dose-rate radiation remain widely reimbursed, entrenched alternatives, particularly for patients who are poor surgical candidates.
• Other focal/ablative technologies — Cryoablation, trans-rectal HIFU, irreversible electroporation, and water-vapor (steam) ablation compete directly for the same focal-therapy niche; unlike TULSA-PRO, none combine real-time MRI thermometry with whole-gland or focal flexibility in a single incision-free procedure.
• Active surveillance and hormone therapy — For lower-risk patients, "watch and wait" monitoring and androgen-deprivation therapy remain lower-cost alternatives to any procedural intervention, capping the addressable near-term patient pool.

Profound's differentiated position is real-time MRI thermal feedback during ablation, which it argues gives physicians more precise control and fewer side effects than cryoablation or HIFU alternatives that lack live MRI guidance — but this is a clinical/technical edge that must still be proven out against surgery and radiation at scale through ongoing trials like CAPTAIN.

---

4. Strategic Strengths & Risks

Strengths

• First-Mover Reimbursement Advantage: Being the first (and, as of the 2025 filing, only) MRI-guided therapeutic ultrasound procedure with Category I CPT codes gives TULSA-PRO a payer-recognition head start that a follow-on competitor would need years of clinical data to match.
• Deepening Hospital Workflow Embedding: Once a health system invests in capital equipment and trains urology/radiology staff on TULSA-PRO, switching to a different ablation modality requires re-training, new capital approval, and disrupting an established referral pathway — a real, if still developing, switching-cost moat.
• Diversified Platform: Sonalleve's fibroid and orthopedic indications give Profound a second commercial leg beyond prostate disease, reducing (if only partially) single-product concentration risk.

Risks

• Persistent Cash Burn: FY2025 net loss of roughly $42.6 million against $16.1 million of revenue, with operating cash outflow of about $38.2 million for the year, means the company remains dependent on external capital to fund growth; it closed a $36.0 million U.S. registered direct offering and a $6.45 million Canadian private placement in December 2025 specifically to shore up its balance sheet, lifting cash to roughly $59.7 million at year-end.
• Small, Concentrated Revenue Base: With revenue still measured in the tens of millions and a single modality (TULSA-PRO) driving the majority of growth, any adoption slowdown, competitive device launch, or adverse CAPTAIN trial readout would disproportionately affect results.
• Strategic Alternatives Exploration: The company incurred roughly $0.9 million in costs in 2025 related to a strategic-alternatives review (reported publicly as "exploring strategic alternatives"), introducing M&A/ownership-change uncertainty alongside the operating business.
• Reimbursement and Policy Risk: While Category I CPT codes are a durable positive, actual payer coverage decisions, Medicare rate-setting, and potential future policy changes still carry execution risk for realized procedure economics.

---

5. Financial Overview

---

6. Summary Conclusion

Profound Medical's investment case is a classic commercial-stage medtech bet: a technically differentiated, now better-reimbursed device platform (TULSA-PRO) racing to scale its installed base and procedure volume faster than it burns cash. The 2025 Category I CPT code award and a strengthened, freshly-recapitalized balance sheet meaningfully de-risk the next 12–18 months relative to where the company stood mid-year, but the core tension remains unresolved: Profound still loses more than two and a half dollars for every dollar of revenue it generates, and its ultimate success depends on converting reimbursement and clinical-trial tailwinds (CAPTAIN) into a much larger, profitable installed base before it needs to return to capital markets again.